|
A Study to Evaluate the Effects of Anti-HIV Drugs in HIV-Positive Patients Who Also Have Hepatitis C Infection Clinical Trials Facts presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, travels to or treatment with a real dr.. We aren't doctors. Always consult your mD on A Study to Evaluate the Effects of Anti-HIV Drugs in HIV-Positive Patients Who Also Have Hepatitis C Infection conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. A Study to Evaluate the Effects of Anti-HIV Drugs in HIV-Positive Patients Who Also Have Hepatitis C Infection Clinical research trials and A Study to Evaluate the Effects of Anti-HIV Drugs in HIV-Positive Patients Who Also Have Hepatitis C Infection medical trials occur in many of places across the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectiveness of new does drugs. The role of the studies / undertakings is to figure out certain human healthcare questions. Clinical trials are a popular means for doctors, government agencies, and private sector corporations to locate treatments for all forms of circumstances, including A Study to Evaluate the Effects of Anti-HIV Drugs in HIV-Positive Patients Who Also Have Hepatitis C Infection. A Study to Evaluate the Effects of Anti-HIV Drugs in HIV-Positive Patients Who Also Have Hepatitis C Infection Clinical Trials and other clinical trials permit volunteers to get medical treatment options before they are available to the masses. Most times the human subjects acquire treatment for free of charge, and sometimes they are paid for their time. Occasionally there is a cost for a A Study to Evaluate the Effects of Anti-HIV Drugs in HIV-Positive Patients Who Also Have Hepatitis C Infection clinical trial. Participants oftentimes recieve the finest healthcare available for their A Study to Evaluate the Effects of Anti-HIV Drugs in HIV-Positive Patients Who Also Have Hepatitis C Infection condition. Dangers are a reality, nonetheless, and might include extra or frequent physician calls, health hazards (potentially life-endangering), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A Study to Evaluate the Effects of Anti-HIV Drugs in HIV-Positive Patients Who Also Have Hepatitis C Infection A Study to Evaluate the Effects of Anti-HIV Drugs in HIV-Positive Patients Who Also Have Hepatitis C Infection
A Study to Evaluate the Effects of Anti-HIV Drugs in HIV-Positive Patients Who Also Have Hepatitis C Infection
For Condition: HIV Infections,Hepatitis C
Status: Completed
Sponsor(s): National Institute of Allergy and Infectious Diseases (NIAID) ,
Synopsis: This study evaluates patients infected with both HIV and Hepatitis C virus (HCV) who are receiving anti-HIV drugs. The purpose of this study is to learn more about HCV infection in patients whose HIV blood level decreases to less than 500 copies/ml.
Details: Sixty naive patients with HIV and confirmed hepatitis C who are co-enrolled in another AACTG antiretroviral study that involves the testing of HAART (Highly Active Antiretroviral Therapy) are entered on this prospective study. Patients who are defined as naive have never received specific, active antiretroviral agents that sustain viral suppression below the limit of detection (500 copies/ml) or have received those agents for only a very limited time. HAART is defined as therapy which is likely to result in HIV-1 RNA plasma levels less than 500 copies/ml for at least 16 weeks. Plasma is collected and evaluated during the study for additional quantitative measurements: Hepatitis C virus (HCV) by HCV RNA PCR and HIV-1 RNA levels. All evaluations for HIV-1 RNA are obtained from the co-enrolled study at the following time points: Pre-entry, entry, at least 2 measurements before Week 16, Week 16, and at least 1 measurement after Week 16.
Eligibility:
Study Type: Observational, Natural History
Minimum Age/Maximum Age: 13 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria Patients may be eligible for this study if they: - Are HIV-positive and have Hepatitis C. - Have an HIV blood level of at least 2,500 copies/ml 30 days before study entry. - Are co-enrolled in an active adult AIDS clinical trial using anti-HIV treatment. - Are at least 13 years of age (parent or guardian consent required if under 18). Exclusion Criteria Patients will not be eligible for this study if they: - Have liver disease. - Have cancer requiring chemotherapy. - Have Hepatitis B. - Abuse alcohol and/or drugs. - Have received certain antiretroviral (anti-HIV) drugs in the past.
Total Enrollment: 60
Location and Contact Information:
Overall Study Official:
RaymondChung, Study Chair,
Willow Clinic
Menlo Park, California, 94025
United States
Rush Presbyterian - Saint Luke's Med Ctr
Chicago, Illinois, 60612
United States
Univ of Southern California / LA County USC Med Ctr
Los Angeles, California, 900331079
United States
Univ of Puerto Rico
San Juan, , 009365067
Puerto Rico
Division of Inf Diseases/ Indiana Univ Hosp
Indianapolis, Indiana, 46202
United States
Queens Med Ctr
Honolulu, Hawaii, 96816
United States
Case Western Reserve Univ
Cleveland, Ohio, 44106
United States
Stanford Univ Med Ctr
Stanford, California, 943055107
United States
Emory Univ
Atlanta, Georgia, 30308
United States
St Louis Regional Hosp / St Louis Regional Med Ctr
St. Louis, Missouri, 63112
United States
Univ of Texas Galveston
Galveston, Texas, 775550435
United States
Johns Hopkins Hosp
Baltimore, Maryland, 21287
United States
Ohio State Univ Hosp Clinic
Columbus, Ohio, 432101228
United States
Boston Med Ctr
Boston, Massachusetts, 02118
United States
Univ of Pennsylvania at Philadelphia
Philadelphia, Pennsylvania, 19104
United States
San Mateo AIDS Program / Stanford Univ
Stanford, California, 943055107
United States
SUNY / Erie County Med Ctr at Buffalo
Buffalo, New York, 14215
United States
Indiana Univ Hosp
Indianapolis, Indiana, 462025250
United States
Chelsea Ctr
New York City, New York, 10021
United States
Howard Univ
Washington D.C., District of Columbia, 20059
United States
Bellevue Hosp / New York Univ Med Ctr
New York City, New York, 10016
United States
Univ of Miami School of Medicine
Miami, Florida, 331361013
United States
Charity Hosp / Tulane Univ Med School
New Orleans, Louisiana, 70112
United States
Marin County Specialty Clinic
San Rafael, California, 94903
United States
Univ of Rochester Medical Center
Rochester, New York, 14642
United States
Columbia Presbyterian Med Ctr
New York City, New York, 10032
United States
Univ of Colorado Health Sciences Ctr
Denver, Colorado, 80262
United States
Univ of Washington
Seattle, Washington, 98104
United States
Louis A Weiss Memorial Hosp
Chicago, Illinois, 60640
United States
Beth Israel Med Ctr
New York City, New York, 10003
United States
San Francisco Gen Hosp
San Francisco, California, 941102859
United States
Tulane Univ School of Medicine
New Orleans, Louisiana, 70112
United States
Univ of Minnesota
Minneapolis, Minnesota, 55455
United States
Harbor UCLA Med Ctr
Torrance, California, 90502
United States
Cornell Univ Med Ctr
New York City, New York, 10021
United States
Harvard (Massachusetts Gen Hosp)
Boston, Massachusetts, 02114
United States
Cook County Hosp
Chicago, Illinois, 60612
United States
Julio Arroyo
West Columbia, South Carolina, 29169
United States
Univ of California / San Diego Treatment Ctr
San Diego, California, 921036325
United States
Univ of Cincinnati
Cincinnati, Ohio, 452670405
United States
Northwestern Univ Med School
Chicago, Illinois, 60611
United States
Univ of Hawaii
Honolulu, Hawaii, 96816
United States
Univ of North Carolina
Chapel Hill, North Carolina, 275997215
United States
Additional Information:
Study ID Numbers: ACTG 383;
Study Start Date:
Record last reviewed: June 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00001117
Other Hiv Infections Studies:
1. Phase I Safety Study of anti-HIV Immune Serum Globulin (Human)
2. The Effects of Anti-HIV Drugs in HIV-Infected Patients Who Do Not Have AIDS
3. A Study of Nitazoxanide in Patients with AIDS and Diarrhea Caused by Cryptosporidium
4. A Phase I/II Double-Blind Controlled Trial to Determine the Safety and Immunogenicity of HIV-1 MN rgp160 Immuno AG Vaccine Therapy in HIV-Infected Individuals with Greater than or Equal to 500/mm3 CD4+ T Cells and 200-400/mm3 CD4+ T Cells
5. A Pilot Study of OPC-8212 (Vesnarinone) in Persons With AIDS-Related Kaposi's Sarcoma
Related Studies:
Other HIV Infections Clinical Trials
Other Georgia Clinical Trials
Other Atlanta Clinical Trials
A Study to Evaluate the Effects of Anti-HIV Drugs in HIV-Positive Patients Who Also Have Hepatitis C Infection
|
|
|
|
|
|
|
|